These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10861754)

  • 21. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
    Hedlund PO; Ala-Opas M; Brekkan E; Damber JE; Damber L; Hagerman I; Haukaas S; Henriksson P; Iversen P; Pousette A; Rasmussen F; Salo J; Vaage S; Varenhorst E;
    Scand J Urol Nephrol; 2002; 36(6):405-13. PubMed ID: 12623503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Thyroid hormones in metastasizing prostate cancer treated with polyestradiol phosphate].
    Dunzendorfer U; Schulz H
    Z Urol Nephrol; 1982 Jul; 75(7):493-500. PubMed ID: 6183845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium.
    Mikkola A; Ruutu M; Aro J; Rannikko S; Salo J
    Ann Chir Gynaecol; 1999; 88(1):18-21. PubMed ID: 10230677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status].
    Stege R; Carlström K; Hedlund PO; Pousette A; von Schoultz B; Henriksson P
    Urologe A; 1995 Sep; 34(5):398-403. PubMed ID: 7483157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women.
    Baumann A; Fuhrmeister A; Brudny-Klöppel M; Draeger C; Bunte T; Kuhnz W
    Contraception; 1996 Oct; 54(4):235-42. PubMed ID: 8922877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholesterol ester metabolism in plasma during estrogen and antiandrogen treatment in men with carcinoma of the prostate.
    Wallentin L; Varenhorst E
    J Lab Clin Med; 1981 Dec; 98(6):906-16. PubMed ID: 6458644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.
    Lim CN; Salem AH
    Clin Pharmacokinet; 2015 Sep; 54(9):963-73. PubMed ID: 25791895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Endocrine treatment of prostatic cancer. A renaissance for parenteral estrogen].
    Stege R; Sander S
    Tidsskr Nor Laegeforen; 1993 Mar; 113(7):833-5. PubMed ID: 8480286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of oestrogen treatment on serum gonadotrophin bioactivity, immunoreactivity and isohormone distribution, and on immunoreactive inhibin levels, in prostatic cancer patients.
    Matikainen T; Haavisto AM; Permi J; de Kretser D; Huhtaniemi I
    Clin Endocrinol (Oxf); 1994 Jun; 40(6):743-50. PubMed ID: 8033364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
    Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
    J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pretreatment hormone levels in prostatic cancer.
    Haapiainen R; Rannikko S; Alfthan O; Adlercreutz H
    Scand J Urol Nephrol Suppl; 1988; 110():137-43. PubMed ID: 3187401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population.
    Aro J
    Prostate; 1991; 18(2):131-7. PubMed ID: 2006119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of endocrine therapy on plasma steroids in prostatic carcinoma patients.
    Drafta D; Proca E; Schindler AE; Neacşu E; Zamfir V; Neagoe M; Teodosiu D
    Endocrinologie; 1984; 22(3):191-7. PubMed ID: 6494786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Steroid-sensitive proteins, growth hormone and somatomedin C in prostatic cancer: effects of parenteral and oral estrogen therapy.
    Stege R; Fröhlander N; Carlström K; Pousette A; von Schoultz B
    Prostate; 1987; 10(4):333-8. PubMed ID: 2440014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.
    Huggins C; Hodges CV
    J Urol; 2002 Jul; 168(1):9-12. PubMed ID: 12050481
    [No Abstract]   [Full Text] [Related]  

  • 38. Influence of hormone application by subcutaneous injections or steroid-containing silastic implants on human benign hyperplastic prostate tissue transplanted into male nude mice.
    Claus S; Aumüller G; Tunn S; Senge T; Schulze H
    Prostate; 1993; 22(3):199-215. PubMed ID: 7683815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of plasma testosterone and prostate carcinoma size by a redox-based, brain-targeted estrogen delivery system in the rat.
    Rahimy MH; Bodor N; Simpkins JW
    Prostate; 1993; 23(1):79-90. PubMed ID: 8337187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of mepartricin on estradiol and testosterone serum levels and on prostatic estrogen, androgen and adrenergic receptor concentrations in adult rats.
    Re G; Badino P; Odore R; Vigo D; Bonabello A; Rabino S; Capello F; Bruzzese T
    Pharmacol Res; 2001 Aug; 44(2):141-7. PubMed ID: 11516265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.